Biopharmaceutical Market Size, Top Share, Demand, Forecast to 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Biopharmaceutical Market Size Analysis

Global Biopharmaceutical Market Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Vaccines
  1. By Value
4. Recombinant Proteins
  1. By Value
5. Gene Therapies
  1. By Value
6. Cell Therapies
  1. By Value
7. Biosimilars
  1. By Value
8. Hormones
  1. By Value
9. Others
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Autoimmune Diseases
  1. By Value
6. Neurological Disorders
  1. By Value
7. Metabolic Disorders
  1. By Value
8. Hematological Diseases
  1. By Value
9. Rare/Orphan Diseases
  1. By Value
10. Others
  1. By Value
By Manufacturing Type
1. Introduction
  1. Manufacturing Type By Value
2. In-house Manufacturing
  1. By Value
3. Contract Manufacturing (CDMOs)
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. DNA Recombinant Technology
  1. By Value
3. Monoclonal Antibody Technology
  1. By Value
4. Cell Culture Technology
  1. By Value
5. Chromatography
  1. By Value
6. Fermentation Technology
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
5. Specialty Clinics
  1. By Value
6. Others
  1. By Value

North America Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Vaccines
  1. By Value
4. Recombinant Proteins
  1. By Value
5. Gene Therapies
  1. By Value
6. Cell Therapies
  1. By Value
7. Biosimilars
  1. By Value
8. Hormones
  1. By Value
9. Others
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Autoimmune Diseases
  1. By Value
6. Neurological Disorders
  1. By Value
7. Metabolic Disorders
  1. By Value
8. Hematological Diseases
  1. By Value
9. Rare/Orphan Diseases
  1. By Value
10. Others
  1. By Value
By Manufacturing Type
1. Introduction
  1. Manufacturing Type By Value
2. In-house Manufacturing
  1. By Value
3. Contract Manufacturing (CDMOs)
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. DNA Recombinant Technology
  1. By Value
3. Monoclonal Antibody Technology
  1. By Value
4. Cell Culture Technology
  1. By Value
5. Chromatography
  1. By Value
6. Fermentation Technology
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
5. Specialty Clinics
  1. By Value
6. Others
  1. By Value
U.S.
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Monoclonal Antibodies (mAbs)
    1. By Value
  3. Vaccines
    1. By Value
  4. Recombinant Proteins
    1. By Value
  5. Gene Therapies
    1. By Value
  6. Cell Therapies
    1. By Value
  7. Biosimilars
    1. By Value
  8. Hormones
    1. By Value
  9. Others
    1. By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Cardiovascular Diseases
    1. By Value
  5. Autoimmune Diseases
    1. By Value
  6. Neurological Disorders
    1. By Value
  7. Metabolic Disorders
    1. By Value
  8. Hematological Diseases
    1. By Value
  9. Rare/Orphan Diseases
    1. By Value
  10. Others
    1. By Value
3. By Manufacturing Type
  1. Introduction
    1. Manufacturing Type By Value
  2. In-house Manufacturing
    1. By Value
  3. Contract Manufacturing (CDMOs)
    1. By Value
4. By Technology
  1. Introduction
    1. Technology By Value
  2. DNA Recombinant Technology
    1. By Value
  3. Monoclonal Antibody Technology
    1. By Value
  4. Cell Culture Technology
    1. By Value
  5. Chromatography
    1. By Value
  6. Fermentation Technology
    1. By Value
  7. Others
    1. By Value
5. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
  5. Specialty Clinics
    1. By Value
  6. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Vaccines
  1. By Value
4. Recombinant Proteins
  1. By Value
5. Gene Therapies
  1. By Value
6. Cell Therapies
  1. By Value
7. Biosimilars
  1. By Value
8. Hormones
  1. By Value
9. Others
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Autoimmune Diseases
  1. By Value
6. Neurological Disorders
  1. By Value
7. Metabolic Disorders
  1. By Value
8. Hematological Diseases
  1. By Value
9. Rare/Orphan Diseases
  1. By Value
10. Others
  1. By Value
By Manufacturing Type
1. Introduction
  1. Manufacturing Type By Value
2. In-house Manufacturing
  1. By Value
3. Contract Manufacturing (CDMOs)
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. DNA Recombinant Technology
  1. By Value
3. Monoclonal Antibody Technology
  1. By Value
4. Cell Culture Technology
  1. By Value
5. Chromatography
  1. By Value
6. Fermentation Technology
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
5. Specialty Clinics
  1. By Value
6. Others
  1. By Value
U.K.
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Monoclonal Antibodies (mAbs)
    1. By Value
  3. Vaccines
    1. By Value
  4. Recombinant Proteins
    1. By Value
  5. Gene Therapies
    1. By Value
  6. Cell Therapies
    1. By Value
  7. Biosimilars
    1. By Value
  8. Hormones
    1. By Value
  9. Others
    1. By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Cardiovascular Diseases
    1. By Value
  5. Autoimmune Diseases
    1. By Value
  6. Neurological Disorders
    1. By Value
  7. Metabolic Disorders
    1. By Value
  8. Hematological Diseases
    1. By Value
  9. Rare/Orphan Diseases
    1. By Value
  10. Others
    1. By Value
3. By Manufacturing Type
  1. Introduction
    1. Manufacturing Type By Value
  2. In-house Manufacturing
    1. By Value
  3. Contract Manufacturing (CDMOs)
    1. By Value
4. By Technology
  1. Introduction
    1. Technology By Value
  2. DNA Recombinant Technology
    1. By Value
  3. Monoclonal Antibody Technology
    1. By Value
  4. Cell Culture Technology
    1. By Value
  5. Chromatography
    1. By Value
  6. Fermentation Technology
    1. By Value
  7. Others
    1. By Value
5. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
  5. Specialty Clinics
    1. By Value
  6. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Vaccines
  1. By Value
4. Recombinant Proteins
  1. By Value
5. Gene Therapies
  1. By Value
6. Cell Therapies
  1. By Value
7. Biosimilars
  1. By Value
8. Hormones
  1. By Value
9. Others
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Autoimmune Diseases
  1. By Value
6. Neurological Disorders
  1. By Value
7. Metabolic Disorders
  1. By Value
8. Hematological Diseases
  1. By Value
9. Rare/Orphan Diseases
  1. By Value
10. Others
  1. By Value
By Manufacturing Type
1. Introduction
  1. Manufacturing Type By Value
2. In-house Manufacturing
  1. By Value
3. Contract Manufacturing (CDMOs)
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. DNA Recombinant Technology
  1. By Value
3. Monoclonal Antibody Technology
  1. By Value
4. Cell Culture Technology
  1. By Value
5. Chromatography
  1. By Value
6. Fermentation Technology
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
5. Specialty Clinics
  1. By Value
6. Others
  1. By Value
China
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Monoclonal Antibodies (mAbs)
    1. By Value
  3. Vaccines
    1. By Value
  4. Recombinant Proteins
    1. By Value
  5. Gene Therapies
    1. By Value
  6. Cell Therapies
    1. By Value
  7. Biosimilars
    1. By Value
  8. Hormones
    1. By Value
  9. Others
    1. By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Cardiovascular Diseases
    1. By Value
  5. Autoimmune Diseases
    1. By Value
  6. Neurological Disorders
    1. By Value
  7. Metabolic Disorders
    1. By Value
  8. Hematological Diseases
    1. By Value
  9. Rare/Orphan Diseases
    1. By Value
  10. Others
    1. By Value
3. By Manufacturing Type
  1. Introduction
    1. Manufacturing Type By Value
  2. In-house Manufacturing
    1. By Value
  3. Contract Manufacturing (CDMOs)
    1. By Value
4. By Technology
  1. Introduction
    1. Technology By Value
  2. DNA Recombinant Technology
    1. By Value
  3. Monoclonal Antibody Technology
    1. By Value
  4. Cell Culture Technology
    1. By Value
  5. Chromatography
    1. By Value
  6. Fermentation Technology
    1. By Value
  7. Others
    1. By Value
5. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
  5. Specialty Clinics
    1. By Value
  6. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Vaccines
  1. By Value
4. Recombinant Proteins
  1. By Value
5. Gene Therapies
  1. By Value
6. Cell Therapies
  1. By Value
7. Biosimilars
  1. By Value
8. Hormones
  1. By Value
9. Others
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Autoimmune Diseases
  1. By Value
6. Neurological Disorders
  1. By Value
7. Metabolic Disorders
  1. By Value
8. Hematological Diseases
  1. By Value
9. Rare/Orphan Diseases
  1. By Value
10. Others
  1. By Value
By Manufacturing Type
1. Introduction
  1. Manufacturing Type By Value
2. In-house Manufacturing
  1. By Value
3. Contract Manufacturing (CDMOs)
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. DNA Recombinant Technology
  1. By Value
3. Monoclonal Antibody Technology
  1. By Value
4. Cell Culture Technology
  1. By Value
5. Chromatography
  1. By Value
6. Fermentation Technology
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
5. Specialty Clinics
  1. By Value
6. Others
  1. By Value
UAE
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Monoclonal Antibodies (mAbs)
    1. By Value
  3. Vaccines
    1. By Value
  4. Recombinant Proteins
    1. By Value
  5. Gene Therapies
    1. By Value
  6. Cell Therapies
    1. By Value
  7. Biosimilars
    1. By Value
  8. Hormones
    1. By Value
  9. Others
    1. By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Cardiovascular Diseases
    1. By Value
  5. Autoimmune Diseases
    1. By Value
  6. Neurological Disorders
    1. By Value
  7. Metabolic Disorders
    1. By Value
  8. Hematological Diseases
    1. By Value
  9. Rare/Orphan Diseases
    1. By Value
  10. Others
    1. By Value
3. By Manufacturing Type
  1. Introduction
    1. Manufacturing Type By Value
  2. In-house Manufacturing
    1. By Value
  3. Contract Manufacturing (CDMOs)
    1. By Value
4. By Technology
  1. Introduction
    1. Technology By Value
  2. DNA Recombinant Technology
    1. By Value
  3. Monoclonal Antibody Technology
    1. By Value
  4. Cell Culture Technology
    1. By Value
  5. Chromatography
    1. By Value
  6. Fermentation Technology
    1. By Value
  7. Others
    1. By Value
5. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
  5. Specialty Clinics
    1. By Value
  6. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Vaccines
  1. By Value
4. Recombinant Proteins
  1. By Value
5. Gene Therapies
  1. By Value
6. Cell Therapies
  1. By Value
7. Biosimilars
  1. By Value
8. Hormones
  1. By Value
9. Others
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Autoimmune Diseases
  1. By Value
6. Neurological Disorders
  1. By Value
7. Metabolic Disorders
  1. By Value
8. Hematological Diseases
  1. By Value
9. Rare/Orphan Diseases
  1. By Value
10. Others
  1. By Value
By Manufacturing Type
1. Introduction
  1. Manufacturing Type By Value
2. In-house Manufacturing
  1. By Value
3. Contract Manufacturing (CDMOs)
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. DNA Recombinant Technology
  1. By Value
3. Monoclonal Antibody Technology
  1. By Value
4. Cell Culture Technology
  1. By Value
5. Chromatography
  1. By Value
6. Fermentation Technology
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
5. Specialty Clinics
  1. By Value
6. Others
  1. By Value
Brazil
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Monoclonal Antibodies (mAbs)
    1. By Value
  3. Vaccines
    1. By Value
  4. Recombinant Proteins
    1. By Value
  5. Gene Therapies
    1. By Value
  6. Cell Therapies
    1. By Value
  7. Biosimilars
    1. By Value
  8. Hormones
    1. By Value
  9. Others
    1. By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Cardiovascular Diseases
    1. By Value
  5. Autoimmune Diseases
    1. By Value
  6. Neurological Disorders
    1. By Value
  7. Metabolic Disorders
    1. By Value
  8. Hematological Diseases
    1. By Value
  9. Rare/Orphan Diseases
    1. By Value
  10. Others
    1. By Value
3. By Manufacturing Type
  1. Introduction
    1. Manufacturing Type By Value
  2. In-house Manufacturing
    1. By Value
  3. Contract Manufacturing (CDMOs)
    1. By Value
4. By Technology
  1. Introduction
    1. Technology By Value
  2. DNA Recombinant Technology
    1. By Value
  3. Monoclonal Antibody Technology
    1. By Value
  4. Cell Culture Technology
    1. By Value
  5. Chromatography
    1. By Value
  6. Fermentation Technology
    1. By Value
  7. Others
    1. By Value
5. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
  5. Specialty Clinics
    1. By Value
  6. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Biopharmaceutical Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Pfizer Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Roche Holding AG
Johnson & Johnson
Amgen Inc.
Novartis AG
Merck & Co., Inc.
AbbVie Inc.
Bristol-Myers Squibb Company
Sanofi S.A.
Gilead Sciences, Inc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment